Evogene Ltd 6-K, filed Dec 19, 2023
Evogene Ltd. (EVGN)
6-K
2023-12-19
For: 2023-12-19
View Original
Added on
April 05, 2026
About this 6-K
Evogene Ltd filed this 6-K on December 19, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2023
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Changes in Management
Evogene Ltd., or Evogene, reports changes in the management of its subsidiary, Casterra Ag Ltd., or Casterra, an
integrated castor cultivation solution company for the bio-based industries:
Mr. Yoash Zohar will be appointed as Chief Executive Officer of Casterra effective as of January 1, 2024. A copy
of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K.
The contents of this Form 6-K, excluding Exhibit 99.1 hereto, are incorporated by reference into the registration statements on Form F-3 (File No. 333-253300) and on Form S-8 (File
Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which
this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: December 19, 2023 |
|
EVOGENE LTD.
(Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer |
EXHIBIT INDEX
|
EXHIBIT NO.
|
DESCRIPTION
|
Exhibit 99.1
 |
 |
Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation
Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's
significant operational expansion
Rehovot, Israel – December 19, 2023 –
Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN; TASE: EVGN) and an integrated castor cultivation solution
company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued
prospects for development, this nomination aims to strengthen its leadership and positioning in the industry.
Casterra entered a new phase in its life cycle of mass production of castor seeds to support the demand for its elite varieties,
addressing the bio-diesel industry's growing needs. To this end, Casterra needs to significantly increase its castor seed production capacity through existing and new subcontractors in target-market locations. Mr. Yoash Zohar, the newly appointed
CEO, brings extensive experience in global agricultural projects, particularly in Africa, along with skills in castor bean cultivation. His professional qualifications align with Casterra's current focus on establishing a robust seed production
system within target geographical territories to support company's expansion.
Casterra's current CEO Mr. Eyal Ronen, who also serves as Evogene's EVP of Business Development, led Casterra's activities for the past
year and a half and will now resume full-time position as EVP BD. Mr. Eyal Ronen will continue to serve as a director on Casterra's Board and support company management in successfully reaching its goals.
Casterra has also significantly expanded its team, including experts in research and development, seed production, and customer support.
This expansion is expected to drive innovation in the company's product offerings, support the anticipated seed production increase, and enhance customer service.
Mr. Ofer Haviv, Casterra's Chairman and
Evogene's CEO, commented, "As Casterra experiences significant growth, I am delighted to welcome Mr. Yoash Zohar as its new CEO. Yoash brings a wealth of expertise in global ag-projects, and I am confident in his ability to propel the
company forward. I would like to express heartfelt gratitude to Mr. Eyal Ronen for his invaluable contributions and look forward to his significant role as a Casterra Board member."
Mr. Yoash Zohar expressed
enthusiasm about the new role, stating, "I am honored to join Casterra as CEO during this pivotal growth phase. Casterra's commitment to innovation and sustainable agricultural solutions, leveraging Evogene's AI technology, aligns with my passion for
driving positive change in the industry. I am excited to advance Casterra's unique offering and lead its team."
About Casterra Ag Ltd.:
Casterra is engaged in developing and commercializing high-yielding castor bean seeds as a cost-competitive, sustainable,
second-generation feedstock for the growing biofuel market. It has built its castor genetic assets based on a broad collection of over 300 castor lines from over 40 different geographic and climatic regions. As part of its development process,
Casterra applies advanced breeding methods utilizing Evogene's Generator AI tech-engine, enabling the use of cutting-edge plant genomics tools
and agro-technique expertise to enable efficient and sustainable industrial-scale production of the castor bean.
For additional information, please visit Casterra's website at: http://www.casterra.com
About Evogene Ltd.: (to place in PR about subsidiaries)
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based
products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI
and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small
molecules (ChemPass AI), and genetic elements (GeneRator
AI).
Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently
utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be
identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking
statement in this press release when it discusses the success of the Casterra’s expansion efforts and plans, Casterra’s castor seed production capacity and expected increase, and Casterra’s ability to establish a robust seed production system within
target geographical territories. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not
guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors,
many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel and Hamas and any worsening of the situation in Israel such as further mobilizations or escalation in the northern
boarder of Israel, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities,
such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience
significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates,
projections, and assumptions.
Evogene Investors' Contact:
Rachel Pomerantz Gerber, Head of Investor Relations at Evogene
Email: rachel.pomerantz@evogene.com
Tel: +972-8-9311901